{"id":1209,"date":"2025-10-17T09:30:32","date_gmt":"2025-10-17T07:30:32","guid":{"rendered":"https:\/\/lensounds.com\/a-propos\/"},"modified":"2026-03-31T13:56:02","modified_gmt":"2026-03-31T11:56:02","slug":"about","status":"publish","type":"page","link":"https:\/\/atonco-pharma.com\/en\/about\/","title":{"rendered":"\u00c0 propos"},"content":{"rendered":"<!-- HERO COVER SECTION -->\n\n<div class=\"wp-block-cover atonco-hero\" style=\"padding-top:180px;padding-right:2rem;padding-bottom:60px;padding-left:2rem;min-height:420px\">\n  <span aria-hidden=\"true\" class=\"wp-block-cover__background has-black-background-color has-background-dim-30 has-background-dim\"><\/span>\n  <img decoding=\"async\" class=\"wp-block-cover__image-background\" alt=\"\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team_background.jpg\" data-object-fit=\"cover\"\/>\n  \n  <div class=\"wp-block-cover__inner-container is-layout-flow wp-block-cover-is-layout-flow\">\n    \n    <div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-530ec779 wp-block-group-is-layout-constrained\">\n      \n      \n      <h1 class=\"wp-block-heading has-white-color has-text-color\" style=\"margin-bottom:16px;font-size:clamp(36px,4.5vw,54px);font-weight:800;line-height:1.1\">Atonco<\/h1>\n      \n      \n      \n      <p class=\"has-text-color\" style=\"color:#eaf1f8;margin-top:0;margin-bottom:0;font-size:clamp(14px, 0.875rem + ((1vw - 3.2px) * 0.556), 20px);\">Alpha-immunotherapy against cancer<\/p>\n      \n      \n    <\/div>\n    \n  <\/div>\n<\/div>\n\n\n<!-- SOUS-MENU DE NAVIGATION -->\n\n<style>\n:root {\n  --atonco-primary: #3167ff;\n  --atonco-secondary: #3ae06a;\n  --atonco-ink: #0d2a3a;\n  --atonco-muted: #4c6678;\n  --atonco-card: #f0f4ff;\n  --atonco-bg: #ffffff;\n  --atonco-border: #b9d0ff;\n  --atonco-radius: 18px;\n  --atonco-shadow-soft: 0 10px 28px rgba(49,103,255,.14), 0 4px 14px rgba(13,42,58,.06);\n  --atonco-shadow-card: 0 18px 52px rgba(49,103,255,.10), 0 6px 18px rgba(13,42,58,.08);\n}\n\n.atonco-hero {\n  position: relative;\n  overflow: hidden;\n}\n\n.atonco-hero:before {\n  content: \"\";\n  position: absolute;\n  inset: 0;\n  background-image:\n    linear-gradient(to right, rgba(255,255,255,.05) 1px, transparent 1px),\n    linear-gradient(to bottom, rgba(255,255,255,.05) 1px, transparent 1px);\n  background-size: 36px 36px;\n  mask-image: linear-gradient(to bottom, black 20%, transparent 100%);\n  pointer-events: none;\n  z-index: 1;\n}\n\n.atonco-submenu-nav {\n  position: sticky;\n  top: 0;\n  z-index: 100;\n  background: #ffffff;\n  border-bottom: 2px solid var(--atonco-border);\n  box-shadow: var(--atonco-shadow-soft);\n}\n\n.atonco-submenu-nav .nav-container {\n  max-width: 1280px;\n  margin: 0 auto;\n  padding: 0 2rem;\n  display: flex;\n  gap: 1rem;\n}\n\n.atonco-submenu-nav button {\n  flex: 1;\n  padding: 1.25rem 2rem;\n  background: transparent;\n  border: none;\n  border-bottom: 3px solid transparent;\n  border-radius: var(--atonco-radius) var(--atonco-radius) 0 0;\n  font-size: 16px;\n  font-weight: 600;\n  color: var(--atonco-muted);\n  cursor: pointer;\n  transition: all 0.3s ease;\n  text-transform: none;\n  letter-spacing: normal;\n}\n\n.atonco-submenu-nav button:hover {\n  color: var(--atonco-primary);\n  background: rgba(49,103,255, 0.05);\n}\n\n.atonco-submenu-nav button.active {\n  color: var(--atonco-primary);\n  border-bottom: 3px solid;\n  border-image: linear-gradient(90deg, var(--atonco-primary) 0%, #414d93 35%, var(--atonco-secondary) 70%, var(--atonco-primary) 100%) 1;\n  background: rgba(49,103,255, 0.08);\n}\n\n.atonco-tab-content {\n  display: none;\n}\n\n.atonco-tab-content.active {\n  display: block;\n  animation: fadeIn 0.4s ease-in;\n}\n\n@keyframes fadeIn {\n  from { opacity: 0; transform: translateY(10px); }\n  to { opacity: 1; transform: translateY(0); }\n}\n\n@media (max-width: 768px) {\n  .atonco-submenu-nav .nav-container {\n    flex-direction: column;\n    padding: 0;\n    gap: 0;\n  }\n\n  .atonco-submenu-nav button {\n    padding: 1rem 1.5rem;\n    font-size: 14px;\n    border-bottom: 1px solid var(--atonco-border);\n    border-radius: 0;\n  }\n\n  .atonco-submenu-nav button.active {\n    border-left: 4px solid;\n    border-image: linear-gradient(180deg, var(--atonco-primary) 0%, #414d93 35%, var(--atonco-secondary) 70%, var(--atonco-primary) 100%) 1;\n    border-bottom: 1px solid var(--atonco-border);\n  }\n}\n\n.circle-icon {\n  display: inline-block;\n  width: 10px;\n  height: 10px;\n  min-width: 10px;\n  min-height: 10px;\n  max-width: 10px;\n  max-height: 10px;\n  border-radius: 50%;\n  background: var(--atonco-primary);\n  flex: 0 0 10px;\n  align-self: center;\n  box-shadow: 0 0 0 3px rgba(49,103,255,0.2);\n}\n\n.circle-icon:after {\n  display: none;\n}\n\n.circle-icon.secondary {\n  background: var(--atonco-secondary);\n  box-shadow: 0 0 0 3px rgba(58,224,106,0.2);\n}\n\n.circle-icon.secondary:after {\n  display: none;\n}\n\n\/* Label with circle icons *\/\np.section-label {\n  display: flex;\n  align-items: center;\n  gap: 4px;\n  color: var(--atonco-primary);\n  font-size: 0.78rem;\n  font-weight: 700;\n  letter-spacing: 0.12em;\n  text-transform: uppercase;\n  margin: 0 0 8px;\n}\n\n\/* WordPress columns layout *\/\n.wp-block-columns {\n  display: flex;\n  flex-wrap: wrap;\n  gap: 1.5rem;\n  align-items: flex-start;\n  width: 100%;\n  box-sizing: border-box;\n}\n\n.wp-block-column {\n  flex-grow: 1;\n  min-width: 0;\n  box-sizing: border-box;\n}\n\n\/* 4-column layout: 25% minus gap *\/\n.wp-block-column[style*=\"flex-basis:25%\"] {\n  flex-basis: calc(25% - 1.125rem) !important;\n  max-width: calc(25% - 1.125rem);\n}\n\n\/* 55%\/45% layout *\/\n.wp-block-column[style*=\"flex-basis:55%\"] {\n  flex-basis: calc(55% - 0.75rem) !important;\n}\n.wp-block-column[style*=\"flex-basis:45%\"] {\n  flex-basis: calc(45% - 0.75rem) !important;\n}\n\n@media (max-width: 900px) {\n  .wp-block-column[style*=\"flex-basis:25%\"],\n  .wp-block-column[style*=\"flex-basis:55%\"],\n  .wp-block-column[style*=\"flex-basis:45%\"] {\n    flex-basis: 100% !important;\n    max-width: 100%;\n  }\n}\n\n.atonco-underline {\n  height: 3px;\n  background: linear-gradient(90deg, var(--atonco-primary) 0%, #414d93 35%, var(--atonco-secondary) 70%, var(--atonco-primary) 100%);\n  width: 180px;\n  margin: 8px 0 32px;\n  border-radius: 2px;\n  box-shadow: 0 10px 30px rgba(0, 0, 0, .08);\n}\n\n.about-section-bg {\n  position: relative;\n  background: linear-gradient(180deg, #ffffff 0%, #f8faff 50%, var(--atonco-card) 100%);\n}\n\n.about-section-bg:before {\n  content: \"\";\n  position: absolute;\n  inset: 0;\n  background-image:\n    linear-gradient(to right, rgba(49,103,255,0.03) 1px, transparent 1px),\n    linear-gradient(to bottom, rgba(49,103,255,0.03) 1px, transparent 1px);\n  background-size: 50px 50px;\n  pointer-events: none;\n}\n\n\/* Inner content max-width constraint handled via inline wrappers *\/\n\n.objective-item {\n  padding: 20px 24px;\n  border-left: 3px solid transparent;\n  background: var(--atonco-bg);\n  border-radius: var(--atonco-radius);\n  border: 1.5px solid var(--atonco-border);\n  box-shadow: var(--atonco-shadow-soft);\n  margin-bottom: 16px;\n  transition: all 0.3s ease;\n}\n\n.objective-item:hover {\n  border-left: 3px solid var(--atonco-primary);\n  background: linear-gradient(90deg, rgba(49,103,255,0.05) 0%, transparent 100%);\n  box-shadow: var(--atonco-shadow-card);\n  transform: translateX(4px);\n}\n\n.objective-item p {\n  margin: 0;\n  color: var(--atonco-muted);\n  line-height: 1.7;\n}\n\n.partnership-card {\n  background: white;\n  border: 2px solid var(--atonco-border);\n  border-radius: var(--atonco-radius);\n  padding: 2.5rem;\n  box-shadow: var(--atonco-shadow-card);\n  transition: all 0.3s ease;\n  position: relative;\n  overflow: hidden;\n  text-align: center;\n  display: flex;\n  flex-direction: column;\n  align-items: center;\n  justify-content: center;\n  min-height: 280px;\n}\n\n.partnership-card:before {\n  content: \"\";\n  position: absolute;\n  top: 0;\n  left: 0;\n  right: 0;\n  height: 4px;\n  background: linear-gradient(90deg, var(--atonco-primary) 0%, #414d93 50%, var(--atonco-secondary) 100%);\n}\n\n.partnership-card:hover {\n  transform: translateY(-6px);\n  box-shadow: 0 24px 68px rgba(49,103,255,.16), 0 8px 22px rgba(13,42,58,.12);\n}\n\n.partnership-logo {\n  max-width: 200px;\n  max-height: 100px;\n  margin-bottom: 1.5rem;\n  object-fit: contain;\n}\n\n.partnership-card h3 {\n  color: var(--atonco-ink);\n  font-size: 22px;\n  font-weight: 700;\n  margin: 0 0 1rem;\n  line-height: 1.3;\n}\n\n.partnership-card p {\n  color: var(--atonco-muted);\n  font-size: 15px;\n  line-height: 1.7;\n  margin: 0;\n}\n<\/style>\n\n<nav class=\"atonco-submenu-nav\">\n  <div class=\"nav-container\">\n    <button class=\"atonco-tab-btn active\" data-tab=\"about\" onclick=\"switchTab('about')\">About<\/button>\n    <button class=\"atonco-tab-btn\" data-tab=\"mission\" onclick=\"switchTab('mission')\">Mission<\/button>\n    <button class=\"atonco-tab-btn\" data-tab=\"team\" onclick=\"switchTab('team')\">Team<\/button>\n    <button class=\"atonco-tab-btn\" data-tab=\"partnerships\" onclick=\"switchTab('partnerships')\">Partnerships<\/button>\n  <\/div>\n<\/nav>\n\n\n<!-- SECTION 1: ABOUT -->\n\n<div id=\"tab-about\" class=\"atonco-tab-content active\">\n\n\n<!-- ABOUT ATONCO SECTION -->\n\n<div class=\"wp-block-group about-section-bg has-global-padding is-layout-constrained wp-container-core-group-is-layout-13906c16 wp-block-group-is-layout-constrained\" style=\"padding-top:5rem;padding-bottom:5rem;\">\n<div style=\"max-width:1280px;margin-left:auto;margin-right:auto;padding-left:2rem;padding-right:2rem;\">\n  \n  <!-- HEADER -->\n  \n  <div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\" style=\"margin-bottom:48px\">\n    \n    \n    <div style=\"display:flex;align-items:center;gap:6px;color:var(--atonco-primary);font-size:0.78rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;width:fit-content;margin-bottom:0;\">\n      <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-primary);box-shadow:0 0 0 3px rgba(49,103,255,0.2);flex:none;\"><\/span>\n      <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-secondary);box-shadow:0 0 0 3px rgba(58,224,106,0.2);flex:none;\"><\/span>\n      About Atonco\n    <\/div>\n    \n    \n    \n    <div class=\"atonco-underline\"><\/div>\n    \n    \n    \n    <h1 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-ink);font-size:clamp(2.1rem,2.2rem + 1.6vw,3.25rem);font-weight:800;letter-spacing:-0.02em;line-height:1.1\">Astatine against cancer<\/h1>\n    \n    \n  <\/div>\n  \n  \n  <!-- CONTENT GRID -->\n  \n  <div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-c3f03267 wp-block-columns-is-layout-flex\">\n    \n    \n    <div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:55%\">\n      \n      \n      <p class=\"has-text-color\" style=\"color:var(--atonco-muted);margin-bottom:1.5rem;font-size:1.08rem;line-height:1.7\">Atonco is a clinical-stage radiopharmaceutical company developing innovative radiopharmaceutical products using astatine-211, an alpha particle-emitting radionuclide for the treatment of cancer. Founded in 2019 and built with an experienced and passionate team, Atonco was established on an exclusive license agreement with Telix Pharmaceuticals for the use of an antibody and a proprietary innovative astatine-211 radiolabeling technology targeting non-muscle-invasive bladder tumors (NMIBT).<\/p>\n      \n      \n      \n      <p class=\"has-text-color\" style=\"color:var(--atonco-muted);margin-bottom:2rem;font-size:1.08rem;line-height:1.7\">Atonco, based on a disruptive and innovative alpha-immunotherapy, addresses two objectives:<\/p>\n      \n      \n      <!-- OBJECTIVES -->\n      \n      <div class=\"objective-item\">\n        <p><strong style=\"color: var(--atonco-primary);\">\u2192<\/strong> Clinical indications with genuine unmet therapeutic needs<\/p>\n      <\/div>\n      \n      <div class=\"objective-item\">\n        <p><strong style=\"color: var(--atonco-primary);\">\u2192<\/strong> Rapidly accessible tumor targets, adapted to the short half-life of astatine-211 (7.2h) and whose small size is suited to the very short path length of the emitted alpha particles<\/p>\n      <\/div>\n      \n      \n    <\/div>\n    \n    \n    \n    <div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:45%\">\n      \n      \n      <figure class=\"wp-block-image size-large has-custom-border\">\n        <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/atonco-astate.jpg\" alt=\"Atonco Pharma - Alpha-immunotherapy\" style=\"border-radius:var(--atonco-radius);box-shadow:var(--atonco-shadow-card)\"\/>\n        <figcaption style=\"text-align:center;font-size:0.8rem;color:#8a9bb5;margin-top:8px;\">Source: Cyclotron Arronax (Wikipedia)<\/figcaption>\n      <\/figure>\n      \n      \n      \n      <div style=\"position:relative;padding-top:56.25%;border-radius:12px;overflow:hidden;box-shadow:0 10px 30px rgba(0,0,0,0.15);margin-top:24px;\">\n        <iframe src=\"https:\/\/player.mediadelivery.net\/embed\/533463\/8794a8ad-c0e2-4db5-992f-8e6043f4af04\" loading=\"lazy\" style=\"border:none;position:absolute;top:0;left:0;height:100%;width:100%;\" allow=\"accelerometer;gyroscope;encrypted-media;picture-in-picture;\" allowfullscreen=\"true\"><\/iframe>\n      <\/div>\n      \n      \n    <\/div>\n    \n    \n  <\/div>\n  \n  \n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n<!-- SECTION 2: MISSION AND VISION -->\n\n<div id=\"tab-mission\" class=\"atonco-tab-content\">\n\n\n<!-- Mission and Vision Section -->\n\n<div class=\"wp-block-group about-section-bg has-global-padding is-layout-constrained wp-container-core-group-is-layout-13906c16 wp-block-group-is-layout-constrained\" style=\"padding-top:5rem;padding-bottom:5rem;\">\n<div style=\"max-width:1280px;margin-left:auto;margin-right:auto;padding-left:2rem;padding-right:2rem;\">\n  \n  <!-- HEADER -->\n  <div class=\"wp-block-group\" style=\"margin-bottom:48px\">\n    \n    <div style=\"display:flex;align-items:center;gap:6px;color:var(--atonco-primary);font-size:0.78rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;width:fit-content;margin-bottom:0;\">\n      <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-primary);box-shadow:0 0 0 3px rgba(49,103,255,0.2);flex:none;\"><\/span>\n      <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-secondary);box-shadow:0 0 0 3px rgba(58,224,106,0.2);flex:none;\"><\/span>\n      Mission\n    <\/div>\n    \n    \n    <div class=\"atonco-underline\"><\/div>\n    \n    \n    <h1 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-ink);font-size:clamp(2.1rem,2.2rem + 1.6vw,3.25rem);font-weight:800;letter-spacing:-0.02em;line-height:1.1\">Offering cancer patients a longer life of better quality<\/h1>\n    \n  <\/div>\n  \n  <!-- MISSION CONTENT -->\n  <div class=\"wp-block-group\" style=\"margin-bottom:4rem\">\n    \n    <p class=\"has-text-color\" style=\"color:var(--atonco-muted);font-size:1.08rem;line-height:1.7\">The Atonco team aims to offer patients an innovative therapy to destroy the last remaining cancer cells of residual disease left after conventional cancer treatments, including radiotherapy, chemotherapy, and immunotherapy.<\/p>\n    \n  <\/div>\n  \n  <!-- FUTURE VISION -->\n  <div class=\"wp-block-group has-white-background-color has-background\" style=\"border-radius:var(--atonco-radius);border:1.5px solid var(--atonco-border);padding:3rem 2.5rem;box-shadow:var(--atonco-shadow-card)\">\n    \n    <h3 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-ink);margin-bottom:1.5rem;font-size:clamp(20px, 2vw, 26px);font-weight:700;line-height:1.3\">Future vision<\/h3>\n    \n    <p class=\"has-text-color\" style=\"color:var(--atonco-muted);font-size:1.1rem;font-style:italic;line-height:1.8\">&#8220;We believe that alpha-immunotherapy using astatine-211 holds great promise in selected clinical indications. Our vision is to confirm the future of alpha-immunotherapy as a promising targeted radiotherapy for better quality and longer lives for cancer patients.&#8221;<\/p>\n    \n  <\/div>\n\n<\/div>  \n<\/div>\n\n\n\n<\/div>\n\n\n<!-- SECTION 3: TEAM (BOARD & MANAGEMENT) -->\n\n<div id=\"tab-team\" class=\"atonco-tab-content\">\n\n\n<!-- TEAM SECTION STYLES -->\n\n<style>\n.team-member-bio {\n  margin-top: 1.5rem;\n}\n\n.bio-actions {\n  display: flex;\n  align-items: center;\n  gap: 1rem;\n  margin-bottom: 1rem;\n}\n\n.linkedin-link {\n  display: inline-flex;\n  align-items: center;\n  justify-content: center;\n  width: 44px;\n  height: 44px;\n  background: #0077b5;\n  border-radius: 8px;\n  transition: all 0.3s ease;\n  text-decoration: none;\n}\n\n.linkedin-link:hover {\n  background: #005885;\n  transform: translateY(-2px);\n  box-shadow: 0 4px 12px rgba(0, 119, 181, 0.3);\n}\n\n.linkedin-link svg {\n  width: 22px;\n  height: 22px;\n  fill: white;\n}\n\n.read-more-btn {\n  background: var(--atonco-primary);\n  color: white;\n  border: none;\n  padding: 10px 24px;\n  border-radius: 999px;\n  font-size: 14px;\n  font-weight: 600;\n  cursor: pointer;\n  transition: all 0.3s ease;\n}\n\n.read-more-btn:hover {\n  background: #2556e8;\n  transform: translateY(-2px);\n  box-shadow: 0 6px 20px rgba(49, 103, 255, 0.4);\n}\n\n.bio-text {\n  display: none;\n  margin-top: 1rem;\n  animation: fadeInBio 0.3s ease-in;\n}\n\n.bio-text.active {\n  display: block;\n}\n\n@keyframes fadeInBio {\n  from {\n    opacity: 0;\n    transform: translateY(-10px);\n  }\n  to {\n    opacity: 1;\n    transform: translateY(0);\n  }\n}\n\n.team-member-card {\n  background: var(--atonco-bg);\n  border-radius: var(--atonco-radius);\n  border: 1.5px solid var(--atonco-border);\n  box-shadow: var(--atonco-shadow-soft);\n  padding: 28px;\n  transition: all 0.3s ease;\n  display: flex;\n  flex-direction: column;\n}\n\n.team-member-card:hover {\n  box-shadow: var(--atonco-shadow-card);\n  transform: translateY(-4px);\n}\n\n.team-title-underline {\n  height: 3px;\n  background: linear-gradient(90deg, var(--atonco-primary) 0%, var(--atonco-secondary) 100%);\n  width: 60px;\n  margin: 12px 0 20px;\n  border-radius: 2px;\n}\n\n.team-section-divider {\n  margin: 4rem 0 3rem;\n  padding-top: 3rem;\n  border-top: 2px solid var(--atonco-border);\n}\n<\/style>\n\n\n<!-- Team Header Section -->\n\n<div class=\"wp-block-group about-section-bg has-global-padding is-layout-constrained wp-container-core-group-is-layout-7045ebe7 wp-block-group-is-layout-constrained\" style=\"padding-top:5rem;padding-bottom:3rem;\">\n<div style=\"max-width:1280px;margin-left:auto;margin-right:auto;padding-left:2rem;padding-right:2rem;\">\n  \n  <div class=\"wp-block-group\" style=\"margin-bottom:48px\">\n    \n    <div style=\"display:flex;align-items:center;gap:6px;color:var(--atonco-primary);font-size:0.78rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;width:fit-content;margin-bottom:0;\">\n      <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-primary);box-shadow:0 0 0 3px rgba(49,103,255,0.2);flex:none;\"><\/span>\n      <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-secondary);box-shadow:0 0 0 3px rgba(58,224,106,0.2);flex:none;\"><\/span>\n      Team\n    <\/div>\n    \n    \n    <div class=\"atonco-underline\"><\/div>\n    \n    \n    <h1 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-ink);font-size:clamp(2.1rem,2.2rem + 1.6vw,3.25rem);font-weight:800;letter-spacing:-0.02em;line-height:1.1\">A team of passionate experts<\/h1>\n    \n  <\/div>\n  \n  <p class=\"has-text-color\" style=\"color:var(--atonco-muted);margin-top:1rem;font-size:1.15rem;line-height:1.7\">The Atonco team includes researchers, healthcare professionals, and medical industry experts who are highly experienced in their respective fields and very confident in the future of alpha-immunotherapy.<\/p>\n\n<\/div>\n<\/div>\n\n\n<!-- Leadership Team -->\n<div class=\"wp-block-group has-white-background-color has-background\" style=\"padding-top:0;padding-bottom:2rem;\">\n<div style=\"max-width:1280px;margin-left:auto;margin-right:auto;padding-left:2rem;padding-right:2rem;\">\n\n  <!-- FIRST ROW - 4 profiles -->\n  \n  <div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-6e030b74 wp-block-columns-is-layout-flex\">\n    \n    <!-- 1. Jean-Fran\u00e7ois CHATAL -->\n    \n    <div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\">\n      \n      <div class=\"team-member-card\">\n        <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team1.jpg\" alt=\"Jean-Fran\u00e7ois Chatal\" style=\"border-radius:var(--atonco-radius);width:100%;height:auto;margin-bottom:1.5rem;object-fit:cover;aspect-ratio:1\/1;\"\/>\n        \n        <h3 style=\"margin:0 0 4px;color:var(--atonco-ink);font-size:20px;font-weight:700;line-height:1.3;\">Jean-Fran\u00e7ois Chatal, MD, PhD<\/h3>\n        <p style=\"margin:0;color:var(--atonco-primary);font-size:14px;font-weight:600;\">Founder, CMO (Chief Medical Officer)<\/p>\n        <div class=\"team-title-underline\"><\/div>\n        \n        <div class=\"team-member-bio\">\n          <div class=\"bio-actions\">\n            <a href=\"#\" class=\"linkedin-link\" target=\"_blank\" rel=\"noopener\">\n              <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 24 24\">\n                <path d=\"M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z\"\/>\n              <\/svg>\n            <\/a>\n            <button class=\"read-more-btn\" onclick=\"toggleBio(this)\">Read more<\/button>\n          <\/div>\n          <div class=\"bio-text\">\n            <p style=\"color:var(--atonco-muted);font-size:14px;line-height:1.65\">Jean-Fran\u00e7ois Chatal, a pioneer in nuclear medicine, is an emeritus professor at the University of Nantes and the author of 204 publications. He served as head of the nuclear medicine departments at the Nantes University Hospital (CHU) and the cancer institute (ICC). He founded an INSERM laboratory at the University of Nantes (CRCINA) dedicated to the diagnostic and therapeutic use of radiolabeled monoclonal antibodies in oncology. In collaboration with Jacques Barbet from Immunotech, they were the first to demonstrate the relevance of pretargeting based on antibody use with a survival benefit of a radioimmunotherapeutic solution in a solid tumor. Their results targeting thyroid cancer were published in 2006 in the Journal of Clinical Oncology. Together with colleagues at the University of Nantes and with support from the Pays de la Loire region and the French government, Jean-Fran\u00e7ois initiated the installation of a high-energy\/high-intensity cyclotron, Arronax, in 2010 for the production of innovative radionuclides. He is also a co-founder of Atlab-Pharma in 2008 (sold to Telix in 2018), a company dedicated to the industrial development of radiolabeled antibodies for radioimmunotherapy, and of Naogen Pharma founded in 2016, a company developing a Rubidium-82 generator for cardiac imaging by Positron Emission Tomography (PET). In 2013, he was honored in Paris with the &#8220;Antoine Beclere Medal&#8221; awarded for his work in the development of nuclear medicine.<\/p>\n          <\/div>\n        <\/div>\n      <\/div>\n      \n    <\/div>\n    \n    \n    <!-- 2. Sylvain FANIER -->\n    \n    <div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\">\n      \n      <div class=\"team-member-card\">\n        <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team2.jpg\" alt=\"Sylvain Fanier\" style=\"border-radius:var(--atonco-radius);width:100%;height:auto;margin-bottom:1.5rem;object-fit:cover;aspect-ratio:1\/1;\"\/>\n        \n        <h3 style=\"margin:0 0 4px;color:var(--atonco-ink);font-size:20px;font-weight:700;line-height:1.3;\">Sylvain Fanier, MSc, EMBA<\/h3>\n        <p style=\"margin:0;color:var(--atonco-primary);font-size:14px;font-weight:600;\">President<\/p>\n        <div class=\"team-title-underline\"><\/div>\n        \n        <div class=\"team-member-bio\">\n          <div class=\"bio-actions\">\n            <a href=\"https:\/\/fr.linkedin.com\/in\/sylvainfanier\" class=\"linkedin-link\" target=\"_blank\" rel=\"noopener\">\n              <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 24 24\">\n                <path d=\"M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z\"\/>\n              <\/svg>\n            <\/a>\n            <button class=\"read-more-btn\" onclick=\"toggleBio(this)\">Read more<\/button>\n          <\/div>\n          <div class=\"bio-text\">\n            <p style=\"color:var(--atonco-muted);font-size:14px;line-height:1.65\">Sylvain Fanier has dedicated his career to overseeing and leading the development of several global medical innovations in the healthcare sector, including neurosurgery, oncology, pain management, cardiovascular, electrophysiology, atrial fibrillation, 3D navigation systems, ultrasound, signal processing, radiation protection, shock waves, and molecular imaging and alpha-immunotherapy. He brings to the company leadership in strategy and a global perspective on business and financing, acquired over the past 30 years in large groups such as Johnson &#038; Johnson and CR Bard, as well as in medical start-ups. Specializing in disruptive medical innovation, he has supported the success of innovative companies such as Lemerpax, Cardioinsight, Sonoscanner, Soundbite Medical Solutions, Surgivisio, and Med-Innov through his consulting firm, Novariver. He holds a degree in Biochemistry and a Master&#8217;s in Physiology from Paul Sabatier University in Toulouse. He also holds an EMBA from ESSEC, Paris, France. Sylvain is a board member of Soundbite Medical Solutions Inc. (Montreal, Canada) and a member of the strategic committees of Ecential Robotics SAS (Grenoble, France), Naogen Pharma, and Atonco (Nantes, France).<\/p>\n          <\/div>\n        <\/div>\n      <\/div>\n      \n    <\/div>\n    \n    \n    <!-- 3. Alexandra PAILLARD -->\n    \n    <div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\">\n      \n      <div class=\"team-member-card\">\n        <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team4.jpg\" alt=\"Alexandra Paillard\" style=\"border-radius:var(--atonco-radius);width:100%;height:auto;margin-bottom:1.5rem;object-fit:cover;aspect-ratio:1\/1;\"\/>\n        \n        <h3 style=\"margin:0 0 4px;color:var(--atonco-ink);font-size:20px;font-weight:700;line-height:1.3;\">Alexandra (Giteau) Paillard, PharmD, PhD<\/h3>\n        <p style=\"margin:0;color:var(--atonco-primary);font-size:14px;font-weight:600;\">COO (Chief Operating Officer)<\/p>\n        <div class=\"team-title-underline\"><\/div>\n        \n        <div class=\"team-member-bio\">\n          <div class=\"bio-actions\">\n            <a href=\"https:\/\/www.linkedin.com\/in\/alexandra-paillard-04b79080\/\" class=\"linkedin-link\" target=\"_blank\" rel=\"noopener\">\n              <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 24 24\">\n                <path d=\"M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z\"\/>\n              <\/svg>\n            <\/a>\n            <button class=\"read-more-btn\" onclick=\"toggleBio(this)\">Read more<\/button>\n          <\/div>\n          <div class=\"bio-text\">\n            <p style=\"color:var(--atonco-muted);font-size:14px;line-height:1.65\">Alexandra holds a Doctor of Pharmacy degree with more than twenty years of experience in Pharmaceutical Development, Quality Assurance, and CMC Regulatory Affairs. She began her career researching protein vectorization at the MINT \u2013 INSERM1066 laboratory at the University of Angers. Alexandra then worked on bringing medicines to market within pharmaceutical laboratories, start-ups, and consulting firms. She managed several pharmaceutical development projects and drafted around ten marketing authorization applications (quality section) at LFB, Biogaran, and ProductLife Group. Alexandra Paillard also contributed to setting up the quality system at the start-up DelleD up to obtaining authorization to open the Exploiting Pharmaceutical Establishment, and was responsible for Quality Assurance at Zach System, a manufacturer of pharmaceutical active ingredients. Today, Alexandra applies her experience at Atonco to the development of innovative radiopharmaceutical products in compliance with radiopharmaceutical regulations. Alexandra holds a Doctor of Pharmacy degree from the University of Angers and a PhD in pharmaceutical technology from the University of Paris-Sud.<\/p>\n          <\/div>\n        <\/div>\n      <\/div>\n      \n    <\/div>\n    \n    \n    <!-- 4. Jacques BARBET -->\n    \n    <div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\">\n      \n      <div class=\"team-member-card\">\n        <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team9.jpg\" alt=\"Jacques Barbet\" style=\"border-radius:var(--atonco-radius);width:100%;height:auto;margin-bottom:1.5rem;object-fit:cover;aspect-ratio:1\/1;\"\/>\n        \n        <h3 style=\"margin:0 0 4px;color:var(--atonco-ink);font-size:20px;font-weight:700;line-height:1.3;\">Jacques Barbet, PhD<\/h3>\n        <p style=\"margin:0;color:var(--atonco-primary);font-size:14px;font-weight:600;\">CSO (Chief Scientific Officer)<\/p>\n        <div class=\"team-title-underline\"><\/div>\n        \n        <div class=\"team-member-bio\">\n          <div class=\"bio-actions\">\n            <a href=\"https:\/\/www.linkedin.com\/in\/jacques-barbet-2864b510\/\" class=\"linkedin-link\" target=\"_blank\" rel=\"noopener\">\n              <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 24 24\">\n                <path d=\"M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z\"\/>\n              <\/svg>\n            <\/a>\n            <button class=\"read-more-btn\" onclick=\"toggleBio(this)\">Read more<\/button>\n          <\/div>\n          <div class=\"bio-text\">\n            <p style=\"color:var(--atonco-muted);font-size:14px;line-height:1.65\">Jacques Barbet brings to Atonco over 40 years of research experience in various fields, particularly in targeting radionuclides to tumor cells for imaging and therapy. Trained as an engineer at the \u00c9cole Polytechnique in Paris, he obtained his doctorate at the University of Paris VI and was appointed Research Director by the CNRS. He settled in Marseille at the Centre d&#8217;Immunologie de Marseille-Luminy, then joined Immunotech SA as head of the pretargeting project. He subsequently joined Jean-Fran\u00e7ois Chatal&#8217;s group in Nantes to help set up GIP Arronax for more than 4 years. He contributed greatly to the development of nuclear medicine research in Nantes by leading the European FP7 TARCC project, the regional research program NucSan, and the PIA ArronaxPlus excellence equipment. In the meantime, he was one of the founding shareholders of Chelatec, Atlab Pharma (now acquired by Telix), and OGD2 Pharma. Retired in 2015 as a research director (exceptional class), he acts as principal scientific advisor for GIP Arronax, Chelatec, OGD2 Pharma, and Atonco.<\/p>\n          <\/div>\n        <\/div>\n      <\/div>\n      \n    <\/div>\n    \n    \n  <\/div>\n  \n  \n  <!-- SECOND ROW - 3 profiles -->\n  \n  <div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-6e030b74 wp-block-columns-is-layout-flex\">\n    \n    <!-- 5. Adrien REYMOND -->\n    \n    <div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\">\n      \n      <div class=\"team-member-card\">\n        <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team3.jpg\" alt=\"Adrien Reymond\" style=\"border-radius:var(--atonco-radius);width:100%;height:auto;margin-bottom:1.5rem;object-fit:cover;aspect-ratio:1\/1;\"\/>\n        \n        <h3 style=\"margin:0 0 4px;color:var(--atonco-ink);font-size:20px;font-weight:700;line-height:1.3;\">Adrien Reymond, PharmD\/B.Eng\/EMBA<\/h3>\n        <p style=\"margin:0;color:var(--atonco-primary);font-size:14px;font-weight:600;\">Business Development Director<\/p>\n        <div class=\"team-title-underline\"><\/div>\n        \n        <div class=\"team-member-bio\">\n          <div class=\"bio-actions\">\n            <a href=\"https:\/\/fr.linkedin.com\/in\/adrien-reymond\" class=\"linkedin-link\" target=\"_blank\" rel=\"noopener\">\n              <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 24 24\">\n                <path d=\"M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z\"\/>\n              <\/svg>\n            <\/a>\n            <button class=\"read-more-btn\" onclick=\"toggleBio(this)\">Read more<\/button>\n          <\/div>\n          <div class=\"bio-text\">\n            <p style=\"color:var(--atonco-muted);font-size:14px;line-height:1.65\">Adrien has more than 18 years of experience in the radiopharmaceutical industry, first as a production pharmacist at Advanced Accelerator Applications (AAA, Novartis), then as Head Pharmacist, President and Managing Director of PETNET Solutions France (Siemens Healthineers). Subsequently, Adrien was radiopharmaceutical project director at Atlanpole Biotherapies, a competitiveness cluster based in Nantes, France, where his role was to help public decision-makers define strategies to support the development of the radiopharmaceutical industry. Adrien has been advising various leaders in the radiopharmaceutical industry since 2018. He is involved in the development of innovative projects for several radiopharmaceutical companies and has developed extensive experience in industrial operations, quality, regulatory and has a wide network in the field of nuclear medicine. Adrien holds a doctorate in Pharmacy from the Claude Bernard University of Lyon, France, a bachelor&#8217;s degree in chemical process engineering from Polytechnique Montr\u00e9al, Canada, and an Executive MBA from Audencia Business School, Nantes.<\/p>\n          <\/div>\n        <\/div>\n      <\/div>\n      \n    <\/div>\n    \n    \n    <!-- 6. Denis BILODEAU -->\n    \n    <div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\">\n      \n      <div class=\"team-member-card\">\n        <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team6.jpg\" alt=\"Denis Bilodeau\" style=\"border-radius:var(--atonco-radius);width:100%;height:auto;margin-bottom:1.5rem;object-fit:cover;aspect-ratio:1\/1;\"\/>\n        \n        <h3 style=\"margin:0 0 4px;color:var(--atonco-ink);font-size:20px;font-weight:700;line-height:1.3;\">Denis Bilodeau, BSc, DIA, MBA<\/h3>\n        <p style=\"margin:0;color:var(--atonco-primary);font-size:14px;font-weight:600;\">Clinical Research Director<\/p>\n        <div class=\"team-title-underline\"><\/div>\n        \n        <div class=\"team-member-bio\">\n          <div class=\"bio-actions\">\n            <a href=\"https:\/\/www.linkedin.com\/in\/denis-bilodeau-41b05710\/\" class=\"linkedin-link\" target=\"_blank\" rel=\"noopener\">\n              <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 24 24\">\n                <path d=\"M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z\"\/>\n              <\/svg>\n            <\/a>\n            <button class=\"read-more-btn\" onclick=\"toggleBio(this)\">Read more<\/button>\n          <\/div>\n          <div class=\"bio-text\">\n            <p style=\"color:var(--atonco-muted);font-size:14px;line-height:1.65\">Denis brings diverse experience in patient care: clinical research on medical devices, pharmaceutical drug development, central laboratories, genomics, medical imaging, and cell therapy, within organizations such as Sandoz, Aventis, Genome Quebec, and the Montreal Heart Institute, at both national and international levels. He led one of Canada&#8217;s largest population genomics registries and has successfully conducted clinical research programs leading to US, Canadian, and European approvals. He is a member of the Ordre des administrateurs agr\u00e9\u00e9s du Qu\u00e9bec. As Clinical Research Director, Denis will work closely with academic clinical research teams to implement Atonco&#8217;s clinical studies, including notably the one targeting bladder cancer. Denis holds an MBA from Concordia University, Montreal, and a BSc from Universit\u00e9 Laval, Quebec.<\/p>\n          <\/div>\n        <\/div>\n      <\/div>\n      \n    <\/div>\n    \n\n    <!-- 7. Cl\u00e9ment MAYEUR -->\n    \n    <div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\">\n      \n      <div class=\"team-member-card\">\n        <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team7.jpg\" alt=\"Cl\u00e9ment Mayeur\" style=\"border-radius:var(--atonco-radius);width:100%;height:auto;margin-bottom:1.5rem;object-fit:cover;aspect-ratio:1\/1;\"\/>\n        \n        <h3 style=\"margin:0 0 4px;color:var(--atonco-ink);font-size:20px;font-weight:700;line-height:1.3;\">Cl\u00e9ment Mayeur<\/h3>\n        <p style=\"margin:0;color:var(--atonco-primary);font-size:14px;font-weight:600;\">CFO (Chief Financial Officer)<\/p>\n        <div class=\"team-title-underline\"><\/div>\n        \n        <div class=\"team-member-bio\">\n          <div class=\"bio-actions\">\n            <a href=\"https:\/\/www.linkedin.com\/in\/clement-mayeur-2a36301\/\" class=\"linkedin-link\" target=\"_blank\" rel=\"noopener\">\n              <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 24 24\">\n                <path d=\"M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z\"\/>\n              <\/svg>\n            <\/a>\n            <button class=\"read-more-btn\" onclick=\"toggleBio(this)\">Read more<\/button>\n          <\/div>\n          <div class=\"bio-text\">\n            <p style=\"color:var(--atonco-muted);font-size:14px;line-height:1.65\">Cl\u00e9ment Mayeur has more than 15 years of experience in corporate finance. He began his career in the audiovisual sector during the creation of the Orange Sport channel, then at TF1 in the mergers and acquisitions of production companies. In parallel, his career was enriched by entrepreneurial experiences that exposed him to the dynamics of company creation and development. After several years as a financial manager and then CFO in an international environment, he became a shared financial director and specialized in the MedTech and Biotech sectors. He brings to the company his expertise in corporate finance and in the implementation of a rigorous financial organization. He holds a master&#8217;s degree from Paris Dauphine University and the University of Reading in business finance, a postgraduate degree in intellectual property from Paris Sorbonne University, and a specialization in corporate finance from EDHEC Business School.<\/p>\n          <\/div>\n        <\/div>\n      <\/div>\n      \n    <\/div>\n    \n    \n    <!-- Empty column for alignment -->\n    \n    <div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\">\n      \n      <div style=\"height:1px;\"><\/div>\n      \n    <\/div>\n    \n    \n  <\/div>\n  \n\n<\/div>\n<\/div>\n<!-- \/wp:post-content -->\n\n\n<!-- Advisors Section -->\n<div class=\"wp-block-group has-white-background-color has-background\" style=\"padding-top:5rem;padding-bottom:5rem;\">\n<div style=\"max-width:1280px;margin-left:auto;margin-right:auto;padding-left:2rem;padding-right:2rem;\">\n    \n<p class=\"has-text-color\" style=\"color:#6b7280;margin-bottom:2rem;font-size:14px;font-weight:700;text-transform:uppercase;letter-spacing:0.05em\">Advisors<\/p>\n\n<!-- 4-COLUMN GRID - ADVISORS -->\n<!-- wp:columns {\"style\":{\"spacing\":{\"blockGap\":\"1.5rem\"}}} -->\n<div class=\"wp-block-columns\">\n\n  <!-- Advisor 1: Jean-Pierre CABOCEL -->\n  <!-- wp:column {\"width\":\"25%\"} -->\n  <div class=\"wp-block-column\" style=\"flex-basis:25%\">\n    <!-- wp:html -->\n    <div class=\"team-member-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team8.jpg\" alt=\"Jean-Pierre Cabocel\" style=\"border-radius:var(--atonco-radius);width:100%;height:auto;margin-bottom:1.5rem;object-fit:cover;aspect-ratio:1\/1;\"\/>\n      \n      <h3 style=\"margin:0 0 4px;color:var(--atonco-ink);font-size:20px;font-weight:700;line-height:1.3;\">Jean-Pierre Cabocel<\/h3>\n      <p style=\"margin:0;color:var(--atonco-primary);font-size:14px;font-weight:600;\">EMBA, PhD Eng<\/p>\n      <div class=\"team-title-underline\"><\/div>\n      \n      <div class=\"team-member-bio\">\n        <div class=\"bio-actions\">\n          <a href=\"#\" class=\"linkedin-link\" target=\"_blank\" rel=\"noopener\">\n            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 24 24\">\n              <path d=\"M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z\"\/>\n            <\/svg>\n          <\/a>\n          <button class=\"read-more-btn\" onclick=\"toggleBio(this)\">Read more<\/button>\n        <\/div>\n        <div class=\"bio-text\">\n          <p style=\"color:var(--atonco-muted);font-size:14px;line-height:1.65\">Jean-Pierre brings to Atonco more than 30 years of experience in the field of nuclear medicine, notably as general manager of the radiopharmaceutical company Cis Bio International (now Curium Pharmaceuticals), a world leader in radiopharmaceuticals for medical imaging. He served as president of the AIPES association (Association of Imaging Producers and Equipment Suppliers), which brings together companies specializing in nuclear medicine, now known as Nuclear Medicine Europe (NME). Jean-Pierre Cabocel holds a doctorate in nuclear physics from the University of Lyon and an MBA from the Institut d&#8217;Administration et de Gestion des Entreprises (IAE) in Lyon.<\/p>\n        <\/div>\n      <\/div>\n    <\/div>\n    <!-- \/wp:html -->\n  <\/div>\n  <!-- \/wp:column -->\n\n  <!-- Advisor 2: Mario CAMPONE -->\n  <!-- wp:column {\"width\":\"25%\"} -->\n  <div class=\"wp-block-column\" style=\"flex-basis:25%\">\n    <!-- wp:html -->\n    <div class=\"team-member-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team10.jpg\" alt=\"Mario Campone\" style=\"border-radius:var(--atonco-radius);width:100%;height:auto;margin-bottom:1.5rem;object-fit:cover;aspect-ratio:1\/1;\"\/>\n      \n      <h3 style=\"margin:0 0 4px;color:var(--atonco-ink);font-size:20px;font-weight:700;line-height:1.3;\">Mario Campone<\/h3>\n      <p style=\"margin:0;color:var(--atonco-primary);font-size:14px;font-weight:600;\">MD, PhD<\/p>\n      <div class=\"team-title-underline\"><\/div>\n      \n      <div class=\"team-member-bio\">\n        <div class=\"bio-actions\">\n          <a href=\"https:\/\/www.linkedin.com\/in\/mario-campone-7272364a\/\" class=\"linkedin-link\" target=\"_blank\" rel=\"noopener\">\n            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 24 24\">\n              <path d=\"M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z\"\/>\n            <\/svg>\n          <\/a>\n          <button class=\"read-more-btn\" onclick=\"toggleBio(this)\">Read more<\/button>\n        <\/div>\n        <div class=\"bio-text\">\n          <p style=\"color:var(--atonco-muted);font-size:14px;line-height:1.65\">Mario Campone has been the general manager of the Institut de Canc\u00e9rologie de l&#8217;Ouest (ICO) since June 2016. He obtained his doctorate at the University of Nantes. In addition, he holds a degree in cell biology and a university doctorate in life and health sciences. Part of his training was carried out at the Beatson Institute in Glasgow (UK). He is a professor of medical oncology at the University of Angers. He heads the phase I unit labeled by the Institut National du Cancer, and leads breast cancer research and translational research at the ICO in interaction with the transcriptomics (Cancer Genomics Joint Unit), proteomics, and bioinformatics platforms. He created the ORPHEO joint group with the National Veterinary School of Nantes. These activities aim to identify prognostic factors for breast cancer as well as predictive factors of response to targeted therapies. Mario Campone has been involved since 2003 in 26 studies as coordinator and principal investigator in 81 clinical studies in breast pathology. He is the author or co-author of more than 300 publications in peer-reviewed journals. He was president of the early study group (2012\u20132016) and vice-president of the personalized medicine group at UNICANCER (2015\u20132019). Since November 2015, he has been scientific director of the &#8220;Canceropole Grand Ouest.&#8221; Since 2019, he has been president of Unicancer (the French hospital network dedicated to fighting cancer).<\/p>\n        <\/div>\n      <\/div>\n    <\/div>\n    <!-- \/wp:html -->\n  <\/div>\n  <!-- \/wp:column -->\n\n  <!-- Advisor 3: Jean-Marc LE DOUSSAL -->\n  <!-- wp:column {\"width\":\"25%\"} -->\n  <div class=\"wp-block-column\" style=\"flex-basis:25%\">\n    <!-- wp:html -->\n    <div class=\"team-member-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team11.jpg\" alt=\"Jean-Marc Le Doussal\" style=\"border-radius:var(--atonco-radius);width:100%;height:auto;margin-bottom:1.5rem;object-fit:cover;aspect-ratio:1\/1;\"\/>\n      \n      <h3 style=\"margin:0 0 4px;color:var(--atonco-ink);font-size:20px;font-weight:700;line-height:1.3;\">Jean-Marc Le Doussal<\/h3>\n      <p style=\"margin:0;color:var(--atonco-primary);font-size:14px;font-weight:600;\">PhD, EMBA<\/p>\n      <div class=\"team-title-underline\"><\/div>\n      \n      <div class=\"team-member-bio\">\n        <div class=\"bio-actions\">\n          <a href=\"https:\/\/www.linkedin.com\/in\/jmledoussal\/\" class=\"linkedin-link\" target=\"_blank\" rel=\"noopener\">\n            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 24 24\">\n              <path d=\"M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z\"\/>\n            <\/svg>\n          <\/a>\n          <button class=\"read-more-btn\" onclick=\"toggleBio(this)\">Read more<\/button>\n        <\/div>\n        <div class=\"bio-text\">\n          <p style=\"color:var(--atonco-muted);font-size:14px;line-height:1.65\">Jean-Marc Le Doussal is the founder and CEO of Remora Biotech, located in Lausanne, in the canton of Vaud, Switzerland. He created and developed Remora Capital SA with partner entrepreneurs to leverage their immunology expertise and, with supporting shareholders, they further develop advanced bio-therapeutic products that could change patients&#8217; lives. In 2008, he founded and chaired ATLAB Pharma SAS, located in Nantes, Pays de la Loire, France. ATLAB Pharma SAS developed an antibody-targeted radiotherapy for the treatment of prostate cancer. It was acquired by Telix Pharmaceuticals located in Melbourne, Australia, in 2018. In 2011, he founded and chaired Activen SA located in Lausanne, Vaud, Switzerland. Activen develops miniproteins for the dermo-cosmetic industry. In 2014, he founded and chaired OGD2 Pharma located in Nantes, Pays de la Loire, France. OGD2 Pharma develops anticancer immunotherapies targeting O-acetylated GD2, a unique antigen with exquisite specificity for cancer compared to normal cells. The targeted clinical indications are deadly pediatric cancers, such as neuroblastoma, and adult cancers such as glioblastoma and triple-negative breast cancer. He is a graduate of the \u00c9cole Polytechnique in Paris, where he obtained a master&#8217;s degree and an engineering diploma. He obtained an Executive MBA in Management, Entrepreneurship, and Innovation from the \u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne, Switzerland.<\/p>\n        <\/div>\n      <\/div>\n    <\/div>\n    <!-- \/wp:html -->\n  <\/div>\n  <!-- \/wp:column -->\n\n  <!-- Advisor 4: Richard Valeix -->\n  <!-- wp:column {\"width\":\"25%\"} -->\n  <div class=\"wp-block-column\" style=\"flex-basis:25%\">\n    <!-- wp:html -->\n    <div class=\"team-member-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/richard-valeix.jpg\" alt=\"Richard Valeix\" style=\"border-radius:var(--atonco-radius);width:100%;height:auto;margin-bottom:1.5rem;object-fit:cover;aspect-ratio:1\/1;\"\/>\n      \n      <h3 style=\"margin:0 0 4px;color:var(--atonco-ink);font-size:20px;font-weight:700;line-height:1.3;\">Richard Valeix<\/h3>\n      <p style=\"margin:0;color:var(--atonco-primary);font-size:14px;font-weight:600;\">MBA<\/p>\n      <div class=\"team-title-underline\"><\/div>\n      \n      <div class=\"team-member-bio\">\n        <div class=\"bio-actions\">\n          <a href=\"#\" class=\"linkedin-link\" target=\"_blank\" rel=\"noopener\">\n            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 24 24\">\n              <path d=\"M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z\"\/>\n            <\/svg>\n          <\/a>\n          <button class=\"read-more-btn\" onclick=\"toggleBio(this)\">Read more<\/button>\n        <\/div>\n        <div class=\"bio-text\">\n          <p style=\"color:var(--atonco-muted);font-size:14px;line-height:1.65\">Richard Valeix is an experienced leader in the biopharmaceutical sector, currently General Manager of the Telix Therapeutics group within Telix Pharmaceuticals Limited. Based in Geneva, he brings more than 20 years of international experience in oncology, endocrinology, and radiopharmaceuticals, combining scientific expertise with strategic vision in commercial and operational development. Holding a Doctor of Pharmacy degree from the University of Pharmacy in Marseille and a Master&#8217;s from ESCP Business School, Richard began his career at Roche Pharmaceuticals in oncology before joining Ipsen, where he held several positions of responsibility in global marketing and business unit management in the therapeutic areas of endocrinology and oncology. He continued his career at Advanced Accelerator Applications (AAA), where he held management positions for more than seven years, including Global Sales and Marketing Director and General Manager for France, Switzerland, and Benelux, actively contributing to the development of nuclear medicine and radioligand therapy solutions.<\/p>\n        <\/div>\n      <\/div>\n    <\/div>\n    <!-- \/wp:html -->\n  <\/div>\n  <!-- \/wp:column -->\n\n<\/div>\n<!-- \/wp:columns -->\n\n<\/div>\n<\/div>\n<!-- \/wp:group -->\n\n<!-- TEAM PHOTO -->\n<div class=\"wp-block-group has-white-background-color has-background\" style=\"padding-top:3rem;padding-bottom:5rem;\">\n<div style=\"max-width:1280px;margin-left:auto;margin-right:auto;padding-left:2rem;padding-right:2rem;\">\n\n<figure class=\"wp-block-image size-full has-custom-border\">\n  <img decoding=\"async\" style=\"display:none\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/atonco-team-2026.jpeg\" alt=\"Atonco Team\" style=\"border-radius:var(--atonco-radius);box-shadow:var(--atonco-shadow-card);width:100%\"\/>\n<\/figure>\n\n<\/div>\n<\/div>\n\n<!-- wp:html -->\n<\/div>\n<!-- \/wp:html -->\n\n<!-- \"PARTNERSHIPS\" TAB -->\n<!-- wp:html -->\n<div id=\"tab-partnerships\" class=\"atonco-tab-content\">\n<!-- \/wp:html -->\n\n<div class=\"wp-block-group about-section-bg\" style=\"padding-top:5rem;padding-bottom:5rem;\">\n<div style=\"max-width:1280px;margin-left:auto;margin-right:auto;padding-left:2rem;padding-right:2rem;\">\n  \n  <!-- HEADER -->\n  <div class=\"wp-block-group\" style=\"margin-bottom:48px\">\n    \n    <div style=\"display:flex;align-items:center;gap:6px;color:var(--atonco-primary);font-size:0.78rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;width:fit-content;margin-bottom:0;\">\n      <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-primary);box-shadow:0 0 0 3px rgba(49,103,255,0.2);flex:none;\"><\/span>\n      <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-secondary);box-shadow:0 0 0 3px rgba(58,224,106,0.2);flex:none;\"><\/span>\n      Partnerships\n    <\/div>\n    \n    <!-- wp:html -->\n    <div class=\"atonco-underline\"><\/div>\n    <!-- \/wp:html -->\n    \n    <h1 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-ink);font-size:clamp(2.1rem,2.2rem + 1.6vw,3.25rem);font-weight:800;letter-spacing:-0.02em;line-height:1.1\">Our strategic partners<\/h1>\n    \n  <\/div>\n  \n  <!-- PARTNERSHIPS CONTENT -->\n  <div class=\"wp-block-group\" style=\"margin-bottom:2rem\">\n    \n    <p class=\"has-text-color\" style=\"color:var(--atonco-muted);font-size:1.08rem;line-height:1.7\">Atonco collaborates with leading partners in the field of pharmaceutical research and medical innovation to accelerate the development of our therapies.<\/p>\n    \n  <\/div>\n  \n  <!-- wp:html -->\n  <div style=\"display:grid;grid-template-columns:repeat(auto-fit,minmax(300px,1fr));gap:2rem;margin-top:2rem\">\n    \n    <div class=\"partnership-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/partenaire1.jpg\" alt=\"Telix Pharmaceuticals\" class=\"partnership-logo\">\n      <h3>Telix Pharmaceuticals<\/h3>\n      <p>An international company specializing in radiopharmaceuticals, Telix develops targeted diagnostic and therapeutic solutions for oncology and other serious conditions, combining medical innovation with precision medicine.<\/p>\n      <p class=\"partnership-link\"><strong>Website:<\/strong> <a href=\"https:\/\/www.telixpharma.com\" target=\"_blank\" rel=\"noopener noreferrer\">www.telixpharma.com<\/a><\/p>\n    <\/div>\n\n    <div class=\"partnership-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/partenaire2.jpg\" alt=\"GIP Arronax\" class=\"partnership-logo\">\n      <h3>GIP Arronax<\/h3>\n      <p>A research platform located in Saint-Herblain (44), dedicated to nuclear medicine, ensuring the production of innovative radionuclides (At-211, Pb-203, Cu-64&#8230;) and radiopharmaceuticals for early clinical phases (Phases 1 and 2).<\/p>\n      <p class=\"partnership-link\"><strong>Website:<\/strong> <a href=\"https:\/\/www.arronax-nantes.fr\" target=\"_blank\" rel=\"noopener noreferrer\">www.arronax-nantes.fr<\/a><\/p>\n    <\/div>\n\n    <div class=\"partnership-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/partenaire3.jpg\" alt=\"CRCI2NA\" class=\"partnership-logo\">\n      <h3>CRCI2NA<\/h3>\n      <p>The Centre de Recherche en Canc\u00e9rologie et Immunologie Nantes-Angers (CRCI2NA) brings together researchers and clinicians to accelerate the discovery of new cancer treatments, from fundamental biology to translational medicine.<\/p>\n      <p class=\"partnership-link\"><strong>Website:<\/strong> <a href=\"https:\/\/crci2na.univ-nantes.fr\" target=\"_blank\" rel=\"noopener noreferrer\">crci2na.univ-nantes.fr<\/a><\/p>\n    <\/div>\n\n    <div class=\"partnership-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/partenaire4.jpg\" alt=\"ICO\" class=\"partnership-logo\">\n      <h3>ICO<\/h3>\n      <p>A reference institution in oncology, the ICO offers cutting-edge expertise across its territory. With its four missions \u2014 care, research, prevention, and education \u2014 the ICO provides patients with personalized care and access to therapeutic innovations.<\/p>\n      <p class=\"partnership-link\"><strong>Website:<\/strong> <a href=\"https:\/\/www.institut-cancerologie-ouest.com\" target=\"_blank\" rel=\"noopener noreferrer\">www.institut-cancerologie-ouest.com<\/a><\/p>\n    <\/div>\n\n    <div class=\"partnership-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/partenaire5.jpg\" alt=\"Minerva Imaging\" class=\"partnership-logo\">\n      <h3>Minerva Imaging<\/h3>\n      <p>Based in Denmark, Minerva Imaging offers preclinical and translational research services, with recognized expertise in molecular imaging, radiopharmacy, and new drug development.<\/p>\n      <p class=\"partnership-link\"><strong>Website:<\/strong> <a href=\"https:\/\/www.minervaimaging.com\" target=\"_blank\" rel=\"noopener noreferrer\">www.minervaimaging.com<\/a><\/p>\n    <\/div>\n\n    <div class=\"partnership-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/partenaire6.jpg\" alt=\"Ionetix\" class=\"partnership-logo\">\n      <h3>Ionetix<\/h3>\n      <p>An American company specializing in radioisotope production, Ionetix designs comprehensive solutions for the manufacturing and distribution of radiopharmaceutical products for research and nuclear medicine.<\/p>\n      <p class=\"partnership-link\"><strong>Website:<\/strong> <a href=\"https:\/\/www.ionetix.com\" target=\"_blank\" rel=\"noopener noreferrer\">www.ionetix.com<\/a><\/p>\n    <\/div>\n\n    <div class=\"partnership-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/partenaire7.jpg\" alt=\"Rigshospitalet\" class=\"partnership-logo\">\n      <h3>Rigshospitalet<\/h3>\n      <p>A major university hospital in Copenhagen, Rigshospitalet is recognized for its cutting-edge clinical research and its leading role in international clinical trials in oncology and radiotherapy.<\/p>\n      <p class=\"partnership-link\"><strong>Website:<\/strong> <a href=\"https:\/\/www.rigshospitalet.dk\" target=\"_blank\" rel=\"noopener noreferrer\">www.rigshospitalet.dk<\/a><\/p>\n    <\/div>\n\n    <div class=\"partnership-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/partenaire8.jpg\" alt=\"University of Michigan\" class=\"partnership-logo\">\n      <h3>University of Michigan<\/h3>\n      <p>A major academic institution in the United States, the University of Michigan is distinguished by its advanced work in biomedical sciences and its collaborations with industry partners for the development of therapeutic biotechnologies.<\/p>\n      <p class=\"partnership-link\"><strong>Website:<\/strong> <a href=\"https:\/\/www.umich.edu\" target=\"_blank\" rel=\"noopener noreferrer\">www.umich.edu<\/a><\/p>\n    <\/div>\n\n    <div class=\"partnership-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/partenaire9.jpg\" alt=\"CHU de Nantes\" class=\"partnership-logo\">\n      <h3>Internal Pharmacy Satellite Unit (APUI) of Nantes University Hospital<\/h3>\n      <p>The Nantes University Hospital has an internal pharmacy satellite unit within the ARRONAX cyclotron. This unit is responsible for the centralized production of radiopharmaceutical medicines for mono- and multi-center clinical trials.<\/p>\n      <p class=\"partnership-link\"><strong>Website:<\/strong> <a href=\"https:\/\/www.chu-nantes.fr\/radiopharmacie\" target=\"_blank\" rel=\"noopener noreferrer\">www.chu-nantes.fr\/radiopharmacie<\/a><\/p>\n    <\/div>\n\n    <div class=\"partnership-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/partenaire10.jpg\" alt=\"Atlanpole\" class=\"partnership-logo\">\n      <h3>Atlanpole<\/h3>\n      <p>A Nantes technopole dedicated to innovation, Atlanpole supports the growth of regional biotech and deeptech companies by fostering synergies between research, industry, and funding.<\/p>\n      <p class=\"partnership-link\"><strong>Website:<\/strong> <a href=\"https:\/\/www.atlanpole.fr\" target=\"_blank\" rel=\"noopener noreferrer\">www.atlanpole.fr<\/a><\/p>\n    <\/div>\n\n    <div class=\"partnership-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/partenaire11.jpg\" alt=\"Atlanpole Bioth\u00e9rapies\" class=\"partnership-logo\">\n      <h3>Atlanpole Bioth\u00e9rapies<\/h3>\n      <p>A national competitiveness cluster, Atlanpole Bioth\u00e9rapies brings together players in biotherapy and radiopharmacy around collaborative projects aimed at accelerating the transition from scientific research to clinical application.<\/p>\n      <p class=\"partnership-link\"><strong>Website:<\/strong> <a href=\"https:\/\/www.atlanpole-biotherapies.eu\" target=\"_blank\" rel=\"noopener noreferrer\">www.atlanpole-biotherapies.eu<\/a><\/p>\n    <\/div>\n\n    <div class=\"partnership-card\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/11\/partenaire12.jpg\" alt=\"French Tech Sant\u00e9\" class=\"partnership-logo\">\n      <h3>CARE en Pays de la Loire<\/h3>\n      <p>CARE en Pays de la Loire brings together regional healthcare players to promote innovation and excellence in the Loire region. This network unites public and private stakeholders committed to developing solutions and initiatives for patients, healthcare professionals, and the territory.<\/p>\n      <p class=\"partnership-link\"><strong>Website:<\/strong> <a href=\"https:\/\/www.lafrenchcare.fr\/\" target=\"_blank\" rel=\"noopener noreferrer\">www.lafrenchcare.fr<\/a><\/p>\n    <\/div>\n\n  <\/div>\n  <!-- \/wp:html -->\n  \n<\/div>\n<\/div>\n<!-- \/wp:group -->\n\n<!-- wp:html -->\n<\/div>\n<!-- \/wp:html -->\n\n<!-- JAVASCRIPT FOR TABS AND BIOS -->\n<!-- wp:html -->\n<script>\nfunction switchTab(tabName) {\n  \/\/ Hide all content\n  document.querySelectorAll('.atonco-tab-content').forEach(function(content) {\n    content.classList.remove('active');\n  });\n\n  \/\/ Deactivate all buttons\n  document.querySelectorAll('.atonco-tab-btn').forEach(function(btn) {\n    btn.classList.remove('active');\n  });\n\n  \/\/ Activate selected content and button\n  document.getElementById('tab-' + tabName).classList.add('active');\n  document.querySelector('[data-tab=\"' + tabName + '\"]').classList.add('active');\n\n  \/\/ Update URL with hash\n  window.location.hash = tabName;\n\n  \/\/ Scroll to sub-menu\n  document.querySelector('.atonco-submenu-nav').scrollIntoView({ behavior: 'smooth', block: 'start' });\n}\n\nfunction toggleBio(button) {\n  const bioContainer = button.closest('.team-member-bio');\n  const bioText = bioContainer.querySelector('.bio-text');\n\n  bioText.classList.toggle('active');\n\n  if (bioText.classList.contains('active')) {\n    button.textContent = 'Read less';\n  } else {\n    button.textContent = 'Read more';\n  }\n}\n\n\/\/ On page load, check if a hash exists in the URL\nwindow.addEventListener('DOMContentLoaded', function() {\n  var hash = window.location.hash.substring(1);\n\n  if (hash && (hash === 'about' || hash === 'mission' || hash === 'team' || hash === 'partnerships')) {\n    switchTab(hash);\n  }\n});\n\n\/\/ Listen for hash changes (browser back button)\nwindow.addEventListener('hashchange', function() {\n  var hash = window.location.hash.substring(1);\n\n  if (hash && (hash === 'about' || hash === 'mission' || hash === 'team' || hash === 'partnerships')) {\n    switchTab(hash);\n  }\n});\n<\/script>\n<!-- \/wp:html -->","protected":false},"excerpt":{"rendered":"<p>About Mission Team Partnerships About Atonco Astatine against cancer Atonco is a clinical-stage radiopharmaceutical company developing innovative radiopharmaceutical products using astatine-211, an alpha particle-emitting radionuclide for the treatment of cancer. Founded in 2019 and built with an experienced and passionate team, Atonco was established on an exclusive license agreement with Telix Pharmaceuticals for the use [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"pulsehome","meta":{"footnotes":""},"class_list":["post-1209","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>About Atonco \u2013 Our mission, team and partnerships | Alpha-immunotherapy<\/title>\n<meta name=\"description\" content=\"Discover Atonco: our mission, experienced team and strategic partnerships. We develop astatine-211 alpha-immunotherapy to eradicate residual cancer cells.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atonco-pharma.com\/en\/about\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"About Atonco \u2013 Our mission, team and partnerships | Alpha-immunotherapy\" \/>\n<meta property=\"og:description\" content=\"Discover Atonco: our mission, experienced team and strategic partnerships. We develop astatine-211 alpha-immunotherapy to eradicate residual cancer cells.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atonco-pharma.com\/en\/about\/\" \/>\n<meta property=\"og:site_name\" content=\"Atonco\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T11:56:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team_background.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"19 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/about\\\/\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/about\\\/\",\"name\":\"About Atonco \u2013 Our mission, team and partnerships | Alpha-immunotherapy\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/about\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/about\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/team_background.jpg\",\"datePublished\":\"2025-10-17T07:30:32+00:00\",\"dateModified\":\"2026-03-31T11:56:02+00:00\",\"description\":\"Discover Atonco: our mission, experienced team and strategic partnerships. We develop astatine-211 alpha-immunotherapy to eradicate residual cancer cells.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/about\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/about\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/about\\\/#primaryimage\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/team_background.jpg\",\"contentUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/team_background.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/about\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c0 propos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\",\"name\":\"Atonco\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"About Atonco \u2013 Our mission, team and partnerships | Alpha-immunotherapy","description":"Discover Atonco: our mission, experienced team and strategic partnerships. We develop astatine-211 alpha-immunotherapy to eradicate residual cancer cells.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atonco-pharma.com\/en\/about\/","og_locale":"en_US","og_type":"article","og_title":"About Atonco \u2013 Our mission, team and partnerships | Alpha-immunotherapy","og_description":"Discover Atonco: our mission, experienced team and strategic partnerships. We develop astatine-211 alpha-immunotherapy to eradicate residual cancer cells.","og_url":"https:\/\/atonco-pharma.com\/en\/about\/","og_site_name":"Atonco","article_modified_time":"2026-03-31T11:56:02+00:00","og_image":[{"url":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team_background.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"19 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/atonco-pharma.com\/en\/about\/","url":"https:\/\/atonco-pharma.com\/en\/about\/","name":"About Atonco \u2013 Our mission, team and partnerships | Alpha-immunotherapy","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/atonco-pharma.com\/en\/about\/#primaryimage"},"image":{"@id":"https:\/\/atonco-pharma.com\/en\/about\/#primaryimage"},"thumbnailUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team_background.jpg","datePublished":"2025-10-17T07:30:32+00:00","dateModified":"2026-03-31T11:56:02+00:00","description":"Discover Atonco: our mission, experienced team and strategic partnerships. We develop astatine-211 alpha-immunotherapy to eradicate residual cancer cells.","breadcrumb":{"@id":"https:\/\/atonco-pharma.com\/en\/about\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atonco-pharma.com\/en\/about\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atonco-pharma.com\/en\/about\/#primaryimage","url":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team_background.jpg","contentUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/team_background.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/atonco-pharma.com\/en\/about\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/atonco-pharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"\u00c0 propos"}]},{"@type":"WebSite","@id":"https:\/\/atonco-pharma.com\/en\/#website","url":"https:\/\/atonco-pharma.com\/en\/","name":"Atonco","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atonco-pharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/pages\/1209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/comments?post=1209"}],"version-history":[{"count":12,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/pages\/1209\/revisions"}],"predecessor-version":[{"id":1339,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/pages\/1209\/revisions\/1339"}],"wp:attachment":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media?parent=1209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}